
Santen Pharmaceutical (($SNPHY)) announced an update on their ongoing clinical study. Study Overview: Santen Pharmaceutical is conducting a Phase III study titled A Phase III Study Including a Single-Arm, Open-Label,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SNPHY | Santen Pharmaceutical Co | 12.59 | 2.68 | 26.99% |
| Name | Price | % Change | |
|---|---|---|---|
| $12.59 | +26.99% |

Santen Pharmaceutical (($SNPHY)) announced an update on their ongoing clinical study. Study Overview: Santen Pharmaceutical is conducting a Phase III study titled A Phase III Study Including a Single-Arm, Open-Label,

Santen Pharmaceutical (($SNPHY)) announced an update on their ongoing clinical study. Study Overview: Santen Pharmaceutical is conducting a Phase III clinical trial titled ‘A Multicenter, Randomized, Double-Masked, Placebo-Controlled Parallel Group

Clearside Biomedical (CLSD) announced today that the Company’s Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical (SNPHY) for ARVN001, branded in the U.S. as

Ocular Therapeutix (OCUL) announced the appointment of Adrienne Graves, Ph.D., to its Board of Directors. As the former CEO of Santen (SNPHY), the US subsidiary of a 130-year-old Japanese pharmaceutical

Citi analyst Hidemaru Yamaguchi upgraded Santen Pharmaceutical to Buy from Neutral with a price target of 1,400 yen, up from 1,100 yen. The analyst says the company’s restructuring-led profit recovery
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 9, 2027TBA | $4.16B | ― | ― | 0.87 | 17.15 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.